...
首页> 外文期刊>Clinical and Translational Allergy >High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis
【24h】

High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis

机译:口服皮质类固醇激素的高暴露和短效β-2激动剂的过度使用与控制药物的处方不足有关:全国电子处方和配药数据库分析

获取原文
           

摘要

Recurrent use of oral corticosteroids (OCS) and over-use of short-acting beta-2-agonists (SABA) are factors associated with adverse side effects and asthma-related death. We aim to quantify high OCS exposure, SABA over-use and its association with prescription and adherence to maintenance treatment for respiratory disease, among patients with prescriptions for respiratory disease, from the Portuguese electronic prescription and dispensing database (BDNP). This was a 1-year (2016) retrospective population-based analysis of a random sample of adult patients from the BDNP, the nationwide compulsory medication prescription system. We assessed high OCS exposure (dispensing?≥?4 packages containing 20 doses of 20?mg each of prednisolone-equivalent, ≥?1600?mg/year) on patients on persistent respiratory treatment (PRT-prescription for ?2 packages of any respiratory maintenance medications). Excessive use of SABA was defined as having a ratio of SABA-to-maintenance treatment ?1 or having SABA over-use (dispensing of ?1?×?200 dose canister/month, of 100?μg of salbutamol-equivalent). Factors associated with high OCS exposure were assessed by multinomial logistic regression. The estimated number of patients on PRT was 4786/100,000 patients. OCS was prescribed to more than 1/5 of the patients on PRT and 101/100,000 were exposed to a high-dose (≥?1600?mg/year). SABA excessive use was found in 144/100,000 patients and SABA over-use in 24/100,000. About 1/6 of SABA over-users were not prescribed any controller medication and 7% of them had a ratio maintenance-to-total ≥?70% (high prescription of maintenance treatment). Primary adherence (median%) to controller medication was 66.7% for PRT patients, 59.6% for patients exposed to high OCS dose and 75.0% for SABA over-users. High OCS exposure or SABA over-use were not associated with primary adherence. High OCS exposure was associated with a maintenance-to-total medication ratio 45?years old and male sex. Exposure to high-dose of OCS (101 per 100,000 patients) and SABA over-use (24 per 100,000) were frequent, and were associated with a low maintenance-to-total prescription ratio but not with primary non-adherence. These results suggest there is a need for initiatives to reduce OCS and SABA inappropriate prescribing.
机译:反复使用口服皮质类固醇(OCS)和过度使用短效β-2-激动剂(SABA)是与不良副作用和哮喘相关死亡相关的因素。我们的目标是从葡萄牙电子处方和配药数据库(BDNP)中量化高OCS暴露量,SABA过度使用及其与处方的相关性以及坚持呼吸道疾病的患者的呼吸道维持治疗的依从性。这是对来自全国强制性药物处方系统BDNP的成年患者的随机样本进行的为期1年(2016年)的回顾性人群分析。我们评估了接受持续呼吸治疗的患者的高OCS暴露量(分配≥4包,每包20毫克泼尼松龙当量,≥1600毫克/年)(对任何≥2包的PRT处方)呼吸维持药物)。过度使用SABA的定义是:SABA与维持治疗的比率>?1或SABA过度使用(分配≥?1?×?200剂量罐/月,相当于100?μg沙丁胺醇的当量) 。通过多项逻辑回归评估与高OCS暴露相关的因素。 PRT的估计患者数为4786 / 100,000。超过1/5的PRT患者被处方OCS,101 / 100,000的患者被暴露于高剂量(≥?1600?mg /年)。 SABA过量使用的患者为144 / 100,000,SABA过量使用的患者为24 / 100,000。约有1/6的SABA过度使用者未服用任何控制药物,其中7%的维持率与总维护率之比≥70%(维持治疗的高处方)。 PRT患者对控制药物的主要依从性(中位数%)为66.7%,暴露于高OCS剂量的患者为59.6%,SABA过度使用者为75.0%。高OCS暴露或SABA过度使用与主要依从性无关。高OCS暴露与45岁以下男性和男性的总体药物维护率有关。高剂量的OCS(每100,000例患者中有101人)和SABA的过度使用(每100,000例中有24人)是经常发生的,并且与低的维持总处方比例有关,但与主要的不依从性无关。这些结果表明,需要采取措施减少OCS和SABA的不当处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号